right place and time, page-7

I would say a little of both Fringedweller. Biotechs as a whole have eased a little. I was mildly surprised when they became the only Australian Biotech to ever show major cancer responses in their very first safety trial, and it was still one of the lowest market caps on the market.
For a company going into phase two trials with earlier stage patients, with major responses against very advanced refractory(chemo resistent) cancers behind them, this price looks cheap to me.The only Australian biotech to ever be in this position as far as I know.
Good luck to Solbec shareholders.